Studies on some immunological profile of patients infected with tuberculosis attending infectious diseases hospital, Kano by Aminu, A.I. & Habib, N.L.
Special Conference Edition, November, 2019
 
Bayero Journal of Pure and Applied Sciences, 12(1): 
ISSN 2006 – 6996 
STUDIES ON SOME IMMUNOLOGICAL PROFILE OF PATIENTS 
INFECTED WITH TUBERCULOSIS ATTENDING INFECTIOUS 
DISEASES HOSPITAL, KANO
Aminu
1Department of Microbiology, Bayero University, Kano, Nigeria
2Infectious Diseases Hospital, Kano, Nigeria
Correspondence author:*
ABSTRACT 
The magnitude of the immune response to tuberculosis (TB) infection also involves cell
mediated immunity comprising numerous types of T
magnitude of the bacterial load and those with the highest load are at a g
developing TB disease. The study assesses the immunological profile (CD4+, CD8+, 
CD3+, CD45+) of TB infected individuals with drug sensitive TB (DS
with that of subjects with Latent Tuberculosis Infection (LTBI) and those
Resistant TB (RR-TB). The study was a cross
Diseases Hospital (IDH), Kano. Two hundred and five (205) subjects participated in the 
study. Collected sputum samples were subjected to Ziehl
cultured on Lowenstein Jensen medium for the identification of Mycobacteria 
tuberculosis. Molecular detection of M. tuberculosis and RR
Xpert® MTB/RIF. Blood samples we
determined using flow cytometry. 
studied subjects were males and 74 were females and that majority of them were in the 
group 14-24years (41.0%), 25
Among the DS-TB and RR-TB groups majority were males (70.8% and 66.7% 
respectively). It was shown that 86.2% and 88.9% of the samples from the DS
RR-TB were AFB positive.  However, all the 65 samples of DS
RR-TB were identified as MTB by culture. All the DS
susceptible TB by Xpert® MTB/RIF, and all the 
rifampicin resistant by the Xpert® MTB/RIF. The study also revealed
(CD4+, CD8+, CD3+ and CD45+) counts of the studied subjects varied significantly 
among the different groups of the study (p<0.05) and that compared to the control and 
the LTBI groups the DS-TB and the RR
order; Control>LTBI>DS-TB>RR




Tuberculosis (TB) remains one of the greatest 
health problems affecting people especially 
those living in developing countries (World 
Health Organisation [WHO], 201
development of drug resistance (
including multidrug resistant TB
extensively DR-TB (XDR-TB) and totally DR
(XXDR-TB) further worsen the situation.
Currently, the WHO reveals that an estimated 10 
million people are infected with TB and 1.3 
million deaths occurs worldwide in 2017 (WHO
2018). Globally, an estimated 
600,000MDR/Rifampicin resistant-TB or RR
cases were reported with 3.5% of new TB cases 
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as MDR/RR-TB. Among cases of MDR
2017, 8.5% were estimated to have extensively 
drug-resistant TB (XDR-TB) (WHO, 2018 & 
2017). Nigeria records 4.3% and 25% MDR
TB/RR-TB among new and old TB cases (WHO, 
2018). 
Studies revealed that TB infection does not 
necessarily lead to disease, only 3 to 10% of 
immune competent individuals that are infected 
will TB develop the disease during their life time, 
while more than 90% of infected subjects 
contain the infection in form of sub
known as Latent Tuberculosis Infection (LTBI) in 
which the pathogen remain in q














et al., 2010).  
S 
Special Conference Edition, November, 2019 
 
Besides the initial physical defense that prevents 
TB infection in most persons exposed to 
tuberculosis, it was reported that protection 
against M. tuberculosis infection is based on the 
cell-mediated immunity (CMI) involving CD4+ 
and CD8+ T-cell subsets, though macrophages 
and dendrintic cells also play important role in 
controlling TB infection (Schoenborn and Wilson, 
2007; Deveci, 2006). CD4 T-cells recognise 
antigenic peptides derived from the phagosomal 
compartment in the context of MHC-class II 
molecule and it was further illustrated that Th 1 
and Th 17 CD4 T cells which are the most 
abundant immune effector cells present in 
alveolar spaces have been involved in protection 
against TB at early stages for their capacity to 
recruit monocytes to the site of granuloma 
(Perrau, 2013; Kaufmann, 2013). Similarly, on 
specific antigen recognition CD8 T-cells 
differentiate into effector cells which produce 
cytolytic molecules and cytokines that kill both 
host cells and intracellular M. tuberculosis 
(Kaufmann, 2013). CD8 T-Lymphocytes 
recognise antigenic peptides which are generally 
loaded in the cytolytic compartment in the 
context of MHC class-I molecules (Dorhoi, et al., 
2012). Doherty and Andersen (2005) reiterated 
that the outcome of infection relies on a balance 
between antigen-specific inflammatory and 
regulatory T cells in both the MHC I- and MHC 
II-restricted T-cell compartments. 
In another study, Kaufmann (2013) illustrated 
that immunological activity against M. 
tuberculosis also involves several conventional 
and unconventional T-cell subsets that are 
characterised by distinct effector functions and 
surface phenotype markers. Among them, 
detailed analysis of paraformaldehyde-fixed-
human tuberculosis tissues revealed that 
apoptotic CD3+ and CD45 RO+ cells are present 
in productive tuberculosis granulomas, 
particularly those harbouring a necrotic center 
(Fayyazi et al., 2000). CD3 is a surface marker 
molecule that characterise human cells involved 
in immune response and present on all T cells 
(Davey, 1993). CD45 is a tyrosine phosphate 
common to all hematopoietic cells and identifies 
leucocytes (Willey, 2008). 
Earlier studies by Doherty and Andersen (2005) 
suggested that the magnitude of the immune 
response to TB infection reflects the magnitude 
of the bacterial load and that those with highest 
load are at a greater risk of developing TB 
disease. In an attempt to establish whether the 
immunological markers could be used to 
differentiate TB infection stages (latent or active 
TB) and type of TB diseases (susceptible TB or 
RR-TB), the study assesses the immunological 
profile (CD4+, CD8+, CD3+, CD45+) of TB 
infected individuals with drug sensitive TB (DS-
TB) and compares it with that of subjects with 
Latent Tuberculosis Infection (LTBI) and those 
with Rifampicin resistance. Such a study would 
not only allow early identification of patients that 
would likely develop the disease but also allow 
patients to be stratified into different groups 
according to disease severity as such allowing 
drug regimens to be administered appropriately 
which enhances adherence and treatment 
outcome. 
 
MATERIALS AND METHODS  
The study area was Kano state in Northern 
Nigeria. It is located within Savanna, latitude 
120 to 120 15’ N and longitude 80 301 to 451 E. 
It has an elevation of about 525 meters above 
the sea level with a population of 12.4 million 
(NIPOST, 2008).  
The study was a cross-sectional study conducted 
at the Infectious Diseases Hospital (IDH), Kano. 
Ethical approval for the study was obtained from 
the Research Ethics Committee of Kano State 
Hospitals Management Board. An informed 
consent was also sought from the participants of 
the study prior to sample collection. Subjects 
with documented history of HIV infection and 
other immunocomprised conditions and those 
who did not provide consent were excluded from 
the study.  
The participants who consented to participate in 
the study are grouped into four groups; the first 
group consists of 46 healthy volunteers who 
have non-detectable delayed-type 
hypersensitivity (DTH) intradermal reaction to 
purified protein derivatives (PPD) and serve as 
the control. The second group consists of 40 
health care workers who have a positive DTH 
response to PPD defining a latent TB Infection 
(LTBI) group. The third group consists of 65 
patients who have been recently diagnosed with 
active pulmonary drug sensitive TB (DS-TB), the 
fourth group consist of 54 patients with 
rifampicin resistant-TB (RR-TB). All the subjects 
were sero-negative to human immunodeficiency 
virus (HIV) infection and non-diabetic. 
Determination of TB status 
Sputum samples were collected and processed 
according to standard mycobacteiological 
procedures described by National Tuberculosis 
and Leprosy Control Programme (NTBLC) SOP 
Manual (2011) and National Committee for 
Clinical Laboratory Standards (NCCLS) (2011). 
Accordingly, the collected sputum samples were 
liquefied with N-acetyl L-cystein (NALC), 
decontaminated with NaOH solution and 
neutralized with Phosphate Buffered Saline 
(PBS) solution and then centrifuged. 
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The sediments were smeared on a clean grease-
free glass slide. After air drying and heat fixing, 
the smeared slide was stained by hot Ziehl-
Neelsen (ZN) staining technique for the 
detection of acid fast bacilli (AFB). The 
sediments were also cultured on Lowenstein 
Jensen (LJ) egg medium. The cultured medium 
was incubated at 37oC for up to six weeks. 
Confirmation and Molecular Detection of 
Rifampicin Resistant M. tuberculosis (RR-
TB) 
Molecular detection of M. tuberculosis and RR-
TB was performed using Xpert® MTB/RIF 
according to the manufacture’s instruction. The 
Xpert® MTB/RIF purifies and concentrates M. 
tuberculosis bacilli from clinical samples. 
Genomic material isolated from the captured 
bacteria by sonication and subsequently 
amplifies the genomic DNA by polymerase chain 
reaction (PCR). Furthermore, the process 
identifies all the clinically relevant rifampicin 
resistance inducing mutations in the RNA 
polymerase beta (rpoB) gene in the M. 
tuberculosis genome in a real time format using 
fluorescent probes called molecular beacons 
(Mulu et al., 2017). 
Determination of Immune Parameters  
Four (4) mls of venous blood was drawn 
aseptically from anterior cubital vein by means 
of vacutainer syringe from the selected 
participants and transferred into vacutainer tube 
containing potassium ethylene diamine tetra 
acetic acid (K2EDTA) as described by 
Cheesbrough (2006).   All the samples collected 
were processed within four hours and analyzed 
on the same day. The patient’s immune 
parameters (CD4, CD8, CD45 and CD3) were 
determined from the blood samples collected on 
flow cytometry (Becton-Dickson FACSCalibur, 
San Jose CA). 
Two sets of Tri-Test reagent kits: one containing 
CD3/CD4/CD45 and the other containing 
CD3/CD8/CD45 were used. Phycoerythrin (PE) 
tagged against monoclonal antibody (MoA) CD4, 
Allophycocyanin (APC) tagged against MoA CD8, 
Peridinin-chlorophyll protein (Per CP) tagged 
against MoA CD45,  and Fluorescein 
isothiocyanate (FITC) tagged against (MoA) 
CD3, were used for absolute count of  CD4+, 
CD8+, CD45+ and CD3+ lymphocytes 
respectively.  
Intradermal Tuberculin Skin Test (TST) 
Intra dermal Tuberculin Skin Test (TST) was 
performed by intradermal injection on the 
forearm of 5 TU (0.1ml) of PPD and the 
indurations read as described by Centers for 
Disease Control and Prevention (CDC) (2013). 
Reactions are classified as positive if induration 
measures ≥ 10mm indicates delayed-type 
hypersensitivity and also indicates past or 
present infection with M. tuberculosis. Whereas, 
induration ≤ 5mm indicates lack of DTH to PPD 
and tuberculosis infection is highly unlikely. 
 
RESULTS  
The result of the study indicated that among the 
205 studied subjects, 46 (22%) were control 
subjects, 40 (19.5%) were LTBI subjects, 64 
(31.7%) were DS-TB patients and 54 (26.3%) 
were patients with RR-TB. The results further 
revealed that 131 of the studied subjects were 
males and 74 were females (Table 1). The Table 
also shows that among the 46 patients identified 
with drug susceptible TB (DS-TB) 70.8% were 
males while 29.2% were females. Similarly, 
among the 54 patients with rifampicin resistant 
TB (RR-TB), 66.7% were males and 33.3% were 
females respectively (Table 1).  
Table 2 shows that majority of the studied 
subjects were in the age group 14-24 years 
(41.0%), 25-34 years (35.6%) and 35-44 years 
(13.7%) respectively. The Table further shows 
that majority of the patients identified with DS-
TB were aged 14-24 years (40%) and 25-34 
years (30.7%). Similarly, among the 54 patients 
with RR-TB, most of them were aged 14-24 
years (24.1%) and 25-34years (46.4%) (Table 
2).  
Table 3 revealed that 86.2% of the samples 
from the DS-TB were identified as AFB positive, 
while 88.9% of the RR-TB samples were AFB 
positive.  Table 3 further shows that all the 65 
samples of DS-TB and 54 samples of the RR-TB 
were identified as MTB by culture. Similarly, all 
the 65 DS-TB samples were detected as 
susceptible TB by Xpert® MTB/RIF, and all the 
54 samples of the RR-TB were identified as 
rifampicin resistant by the Xpert® MTB/RIF. 
Table 4 revealed that the mean T-cell (CD4+, 
CD8+, CD3+ and CD45+) counts of the studied 
subjects varied significantly among the different 
groups of the study (p<0.05) and that compared 
to the control and the LTBI groups, the DS-TB 
and the RR-TB groups recorded the lowest 
counts. Least significance difference (LSD) 
indicated a significance difference in the CD4+, 
CD8+, CD3+ and CD45+ cells counts of the 
studied subjects in the order; Control>LTBI>DS-
TB>RR-TB. Specifically, the Table indicated that 
the highest mean CD4+, CD8+, CD3+ and 
CD45+ cell count of 1081.6cells/µl, 
529.0cells/µl, 994.93cells/µl and 1854.28cells/µl 
were recorded from the control group. 
This is followed by the LTBI group which 
recorded a CD4+, CD8+, CD3+and CD45+ cell.  
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The DS-TB group recorded a CD4+, CD8+, 
CD3+ and CD45+ cell count 684.23cells/µl, 
411.11cells/µl, 882.40cells/µl and 
1308.78cells/µl respectively (Table 4).  For, the 
RR-TB groups CD4+, CD8+, CD3+ and CD45+ 
cell counts were 497.26cells/µl, 352.0 cells/µl, 
700.78cells/µl and 994.3cells/µl respectively 
(Table 4). 
 
Table 1: Sex distribution of the studied subjects 
Sex Tuberculosis Status of the Studied Subjects Total 
Control LTBI DS-TB  RR-TB 
Males 25 (54.3%) 24 (60%) 46 (70.8%) 36 (66.7%) 131 (63.9%) 
Females 21 (45.7%) 16 (40%) 19 (29.2%) 18 (33.3%) 74 (36.1%) 
 46 (22.4%) 40 (19.5%) 65 (31.7%) 54 (26.3%) 205 (100%) 
Key:  LTBI-Latent TB Infection; DS-Drug Susceptible; TB-Tuberculosis; RR-Rifampicin resistance 
 
Table 2: Age distribution of the studied subjects 
Age Tuberculosis Status of the Studied Subjects Total 
Control LTBI DS-TB RR-TB 
14-24 30 (65.2%) 15 (37.5%) 26 (40%) 13 (24.1%) 84 (41.0%) 
25-34 12 (26.1%) 16 (40%) 20 (30.7%)  25 (46.3%) 73 (35.6%) 
35-44 4 (8.7%) 5 (12.5%) 9 (13.8%) 10 (18.5%) 28 (13.7%) 
45-54 0 2 (5%) 7 (10.8%) 5 (9.3%) 14 (6.8%) 
>55 0 25 (5%) 3 (4.6%) 1 (1.6%) 6 (2.9%) 
Total 46 40 65 54 205 
Key:  LTBI-Latent TB Infection; DS-Drug Susceptible; TB-Tuberculosis; RR-Rifampicin resistance 
 
Table 3: Acid Fast Bacilli (microscopy), culture and RR-TB (Xpert) Status of the Studied 
Subjects 
GROUP AFB  CULTURE Xpert 
Positive Negative Positive Negative Positive Negative 
Control  
(n=46)              
0 46 (100%) 0 46 (100%) 0 46 (100%) 
LTBI  (n=40)             0 40 (100%) 0 40 (100%) 0 40 (100%) 
DS-TB (n=65) 56 (86.2%) 9 (13.8%) 65 (100%) 0 0  65 (100%) 
RR-TB (n=54) 48 (88.9%) 6 (11.1%) 54 (100%) 0 54 (100%) 0 












Key:  AFB-Acid fast bacilli; LTBI-Latent TB Infection; DS-Drug Susceptible; TB-Tuberculosis; RR-
Rifampicin resistance 
 
Table 4: Mean T-cell (CD4+, CD8+, CD3+ and CD45+) counts of the studied subjects 
Tuberculosis Status 
of the Studied Subjects 
Mean T-cell counts (cells/µl) 
CD4+ CD8+ CD3+ CD45+ 
Control (n=46) 1081.36 529.0 994.93 1854.28 
LTBI (n=40) 690.03 405.10 963.53 1525.83 
DS-TB (n=65) 684.23 411.11 882.40 1308.78 
RR-TB (n=54) 497.26 352.0 700.78 994.3 
Key:  AFB-Acid fast bacilli; LTBI-Latent TB Infection; DS-Drug Susceptible; TB-Tuberculosis; RR-
Rifampicin resistance 
Note: *F-calculated=29.249, Fdf=3; 0.05=2.604, therefore p<0.05 
*Least significance difference (LSD) indicated a significance difference in the CD4+, CD3+ and 
CD45+ cells counts of the studied subjects in the order: Control>LTBI>DS-TB>RR-TB and the LSD 
indicated a significance difference in the CD8+ cells counts of the studied subjects in the order: 
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DISCUSSION 
The findings of this study revealed that among 
both the DS-TB and the RR-TB patients more 
males were infected with TB than females and 
this coincides with the WHO (2018) reports that 
men are more affected with TB than women. In 
an earlier study, Neyrolles and Quintana-Murci 
(2009) reported a male/female ratio of 1.9±0.6 
among TB patients. Neyrolles and Quintana-
Murci (2009) further pointed out this excess of 
male pulmonary TB cases is seen in all regions 
of the world, and in almost all countries, at least 
in non–HIV-infected patients. They further 
expounded that large prevalence surveys have 
suggested that the sex bias observed in 
pulmonary TB cases may result partly from 
genuine biological differences in male and 
female susceptibility to M. tuberculosis infection 
or the development of TB disease. According to 
Davila et al. (2008), several other, more specific 
biological sex-related factors that may render 
men even more susceptible to pulmonary TB 
than women include: sex steroid hormones, the 
genetic makeup of the sex chromosomes, and 
sex-specific metabolic features.  
The study demonstrates that majority of the 
infected patients are aged between 14 years to 
44years. This may not be unconnected with the 
fact that patients in this category are physically 
active and may be engaged in various sectors of 
life working experiences as such becoming more 
exposed to acquire and develop TB. The WHO 
(2018) reports that 90% of TB is seen among 
adults (aged ≥15 years). 
The study revealed that the traditional culture 
method still remains the gold standard 
diagnostic procedure for identification of TB as 
all the DS-TB and RR-TB samples were identified 
as MTB by culture, whereas 86.2% and 88.9% 
of the samples from the DS-TB and the RR-TB 
samples were AFB positive respectively. 
Similarly, the Xpert® MTB/RIF performed 
excellently as all the DS-TB samples were 
detected as susceptible TB and all the RR-TB 
samples were identified as rifampicin resistant. 
The observation of this study is comparable to 
that of Roce et al. (2017) which shows that, the 
Xpert MTB/RIF revealed sensitivity and 
specificity of 89.6% and 97.2% for the detection 
of MTBC and 100% sensitivity and 98.3% 
specificity for the detection of Rifampicin 
Resistance. Other studies such as those by 
Rahman et al. (2016); Sharma et al. (2015) also 
agree with the observations of this study. In 
their contribution, Arend and van Sooligen 
(2017) opined that the implementation of Xpert 
MTB/RIF since 2010 has revolutionized 
molecular diagnosis of TB which combines early 
diagnosis of TB with direct detection of 
Rifampicin Resistance. They further stated that 
to overcome some of its limitations, the 
performance of Xpert MTB/RIF was re-
engineered to increase its diagnostic sensitivity 
and specificity in the detection of Rifampicin 
Resistance in form of MTP/RIF Ultra (Xpert 
Ultra). 
Mycobacterium tuberculosis resides in lung 
phagocytes and can persist in its host for 
decades, and apart from macrophages which are 
the most abundant host cells at sites of infection 
which have been implicated in both disease 
control and progression (Huang et al. 2018), 
foremost in the anti-mycobacterial immune 
responses are also T lymphocytes especially 
CD4+ and CD8+ T cells which produce various 
cytokines including IFN-γ and display cytolytic 
activity against mycobacteria infected cells 
(Weiss and Schaible, 2015). The present study 
also demonstrated the presence of various T cell 
subsets among the studied subjects with CD45+ 
T cells having higher counts compared to CD4+, 
CD8+ and CD3+ T cells. 
The study further demonstrated that the mean 
T-cell (CD4+, CD8+, CD3+ and CD45+) counts 
varied significantly (p<0.05) among the different 
groups of the study and that compared to the 
control (healthy subjects) and the LTBI groups 
the DS-TB and the RR-TB groups recorded the 
lowest counts. The observation that the mean T 
cell counts of the control and LTBI subjects were 
found to be significantly higher than those of 
DS-TB and RR-TB subjects implies that there is 
profound immunological activity involving the T 
cells denoting accumulation of higher bacterial 
load in the DS-TB and RR-TB subjects compared 
to the Control and LTBI subjects. These 
observations are consistent with earlier studies 
by Ordway et al. (2007) which revealed that 
during the acute and sub-acute stages of TB 
infection the immune response involve the 
recruitment of more CD4+ T cells, including cells 
expressing the activation marker of CD45, but 
few CD8+ T cells. They however show that soon 
afterwards (after 30days) a dramatic loss in the 
CD4 response occurs. Furthermore, in support of 
the hypothesis of an augmented lymphocyte 
pooling in the site of infection, Venturini et al. 
(2019) revealed that there was a reduction of 
CD3+ and CD4+ absolute and percentage 
depletion in active TB (ATB) patients versus 
healthy control (HC) subjects in their study 
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This study further emphasized the role played by 
CD4+ T cells in controlling the activity of other 
cells directed at Mycobacterial infection. For 
example, as the CD4+ T cell count decreases 
among the various studied subjects the CD8+ T 
cell count also decreases. Studies by Yao et al. 
(2014) revealed that CD4+ T cells are needed to 
prevent rapid TB progression and to sustain 
multiple effector functions of CD8+ T and NK-
like cells during M. tuberculosis infection of 
nonhuman primates. They demonstrated that 
CD4+ T cell depletion during M. tuberculosis 
infection leads to early extrapulmonary M. 
tuberculosis dissemination, a subsequent loss of 
systemic/pulmonary responses of multiple 
effector cells, and rapid progression to more 
severe TB in macaques.  
Finally, the findings of this study implies that 
assessment of T cells sub sets particularly CD4+, 
CD+8, CD45 and CD3 T cells may be used in the 
prognosis of DR-TB as evidenced by the least 
significance difference (LSD) which indicated a 
significance difference in the CD4+, CD8+, 
CD3+ and CD45+ cells counts of the studied 




The study revealed that males had the highest 
number of cases and patients aged 21-30 years 
and 31-40 years had the highest number of 
cases. The study also revealed that the T-cell 
counts of the studied subjects varied 
significantly (p<0.05) among the different 
groups of the study and that compared to the 
control and the LTBI groups, the DS-TB and the 
RR-TB groups recorded the lowest counts. This 
implies that assessment of T cells sub-sets may 
be used in the prognosis of DR-TB which will 
enhance early diagnosis & treatment of TB as 
well as strengthen the TB control strategy. 
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